title: Multiple paradoxical adverse events in a patient affected with ankylosing spondylitis treated with TNF blockers.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Lo Nigro
authors.forename: Roberta
authors.initials: R
authors.lastname: Ramonda
authors.forename: Mauro
authors.initials: M
authors.lastname: Alaibac
authors.forename: Valentina
authors.initials: V
authors.lastname: Modesti
authors.forename: Leonardo
authors.initials: L
authors.lastname: Punzi
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects; D003424:Crohn Disease / Q000139:chemically induced; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects; D011565:Psoriasis / Q000139:chemically induced; D018124:Receptors, Tumor Necrosis Factor; D013167:Spondylitis, Ankylosing / Q000150:complications* / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D000068800:Etanercept